Weekly Recap: BRAVNETSA approved and HSR reset to Oct 21, 2026
Lantheus Holdings Inc (NASDAQ:LNTH) won FDA approval for BRAVNETSA (lutetium Lu-177 dotatate) as bioequivalent to LUTATHERA for adult GEP—NETs and plans a staged launch centered on supply, pricing and patient access while an HSR refiling restarts the 30—day review to Oct 21, 2026.Previous Week Reca…